Adaptimmune Therapeutics PLC Sponsored ADR Stock price
Is Adaptimmune Therapeutics PLC Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Adaptimmune Therapeutics PLC Sponsored ADR Stock Analysis
Analyst Opinions
9 Analysts have issued a Adaptimmune Therapeutics PLC Sponsored ADR forecast:
Analyst Opinions
9 Analysts have issued a Adaptimmune Therapeutics PLC Sponsored ADR forecast:
Don't miss a Thing! We will send you all news about Adaptimmune Therapeutics PLC Sponsored ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
| Head office | United Kingdom |
| CEO | Mr. Rawcliffe |
| Employees | 506 |
| Founded | 2008 |
| Website | www.adaptimmune.com |


